Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.

Kinoshita T, Kudo-Saito C, Muramatsu R, Fujita T, Saito M, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Hayashi Y, Kaseda K, Kamiyama I, Ohtsuka T, Tomizawa K, Shimoji M, Mitsudomi T, Asamura H, Kawakami Y.

Eur J Cancer. 2017 Nov;86:15-27. doi: 10.1016/j.ejca.2017.08.026. Epub 2017 Sep 23.

PMID:
28950145
2.

Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid.

Mukai S, Ogawa Y, Urano F, Kudo-Saito C, Kawakami Y, Tsubota K.

Sci Rep. 2017 Feb 6;7:41939. doi: 10.1038/srep41939.

3.

Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.

Kinoshita T, Muramatsu R, Fujita T, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Kudo-Saito C, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H, Kawakami Y.

Ann Oncol. 2016 Nov;27(11):2117-2123. Epub 2016 Aug 8.

PMID:
27502728
4.

Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity.

Kudo-Saito C, Fuwa T, Kawakami Y.

Eur J Cancer. 2016 Jul;62:54-61. doi: 10.1016/j.ejca.2016.04.013. Epub 2016 May 20.

PMID:
27208904
5.

Cancer-associated mesenchymal stem cells aggravate tumor progression.

Kudo-Saito C.

Front Cell Dev Biol. 2015 Apr 1;3:23. doi: 10.3389/fcell.2015.00023. eCollection 2015.

6.

Induction of immunoregulatory CD271+ cells by metastatic tumor cells that express human endogenous retrovirus H.

Kudo-Saito C, Yura M, Yamamoto R, Kawakami Y.

Cancer Res. 2014 Mar 1;74(5):1361-70. doi: 10.1158/0008-5472.CAN-13-1349.

7.

FSTL1 promotes bone metastasis by causing immune dysfunction.

Kudo-Saito C.

Oncoimmunology. 2013 Nov 1;2(11):e26528. Epub 2013 Oct 10.

8.

Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction.

Kudo-Saito C, Fuwa T, Murakami K, Kawakami Y.

Cancer Res. 2013 Oct 15;73(20):6185-93. doi: 10.1158/0008-5472.CAN-13-1364. Epub 2013 Aug 21.

9.

Improvement of cancer immunotherapy by combining molecular targeted therapy.

Kawakami Y, Yaguchi T, Sumimoto H, Kudo-Saito C, Iwata-Kajihara T, Nakamura S, Tsujikawa T, Park JH, Popivanova BK, Miyazaki J, Kawamura N.

Front Oncol. 2013 May 28;3:136. doi: 10.3389/fonc.2013.00136. eCollection 2013.

10.

Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy.

Kawakami Y, Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Iwata-Kajihara T, Nakamura S, Nishio H, Satomi R, Kobayashi A, Tanaka M, Park JH, Kamijuku H, Tsujikawa T, Kawamura N.

Ann N Y Acad Sci. 2013 May;1284:80-6. doi: 10.1111/nyas.12094.

PMID:
23651199
11.

CCL2 is critical for immunosuppression to promote cancer metastasis.

Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N, Kawakami Y.

Clin Exp Metastasis. 2013 Apr;30(4):393-405. doi: 10.1007/s10585-012-9545-6. Epub 2012 Nov 11.

PMID:
23143679
12.

Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells.

Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, Kudo-Saito C, Fujita T, Sumimoto H, Kawakami Y.

J Immunol. 2012 Sep 1;189(5):2110-7. doi: 10.4049/jimmunol.1102282. Epub 2012 Jul 18.

13.

The mechanisms of cancer immunoescape and development of overcoming strategies.

Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y.

Int J Hematol. 2011 Mar;93(3):294-300. doi: 10.1007/s12185-011-0799-6. Epub 2011 Mar 5. Review.

PMID:
21374075
14.

Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y.

Cancer Cell. 2009 Mar 3;15(3):195-206. doi: 10.1016/j.ccr.2009.01.023.

15.

Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.

Mochimaru H, Nagai N, Hasegawa G, Kudo-Saito C, Yaguchi T, Usui Y, Kurihara T, Koto T, Satofuka S, Shinoda H, Ozawa Y, Tsubota K, Kawakami Y, Ishida S.

Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4795-801.

PMID:
17898306
16.

[Current status of gene therapy for cancers].

Kudo-Saito C.

Gan To Kagaku Ryoho. 2007 Sep;34(9):1341-6. Review. Japanese.

PMID:
17876128
17.

Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.

Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW.

Cancer Immunol Immunother. 2007 Dec;56(12):1897-910. Epub 2007 May 15.

PMID:
17503041
18.

Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.

Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, Hodge JW.

Clin Cancer Res. 2007 Mar 15;13(6):1936-46.

19.

Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.

Udagawa M, Kudo-Saito C, Hasegawa G, Yano K, Yamamoto A, Yaguchi M, Toda M, Azuma I, Iwai T, Kawakami Y.

Clin Cancer Res. 2006 Dec 15;12(24):7465-75.

20.

4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL.

Vaccine. 2006 Jun 5;24(23):4975-86. Epub 2006 Mar 31.

21.

TRICOM vector based cancer vaccines.

Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.

Curr Pharm Des. 2006;12(3):351-61. Review.

PMID:
16454749
22.

Costimulatory molecules as adjuvants for immunotherapy.

Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.

Front Biosci. 2006 Jan 1;11:788-803. Review.

PMID:
16146771
23.

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.

Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.

Clin Cancer Res. 2005 Jun 15;11(12):4533-44.

24.

Multiple costimulatory modalities enhance CTL avidity.

Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J.

J Immunol. 2005 May 15;174(10):5994-6004. Erratum in: J Immunol. 2005 Jun 15;174(12):8220.

25.
26.

Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.

Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H.

Cancer Gene Ther. 2004 Oct;11(10):665-80.

PMID:
15354200

Supplemental Content

Loading ...
Support Center